This Phase I, dose-escalation safety study (n=24) evaluated repeated 0.5 mg/kg IV ketamine infusions in adults with treatment-resistant depression.
Open-label, single-centre Phase I dose-escalation study (ReD-KITE) administering 0.5 mg/kg ketamine IV over 40 minutes: stage 1 once weekly for three weeks, stage 2 twice weekly for three weeks; total study duration including follow-up ~3 months.
Primary outcome assessed safety and tolerability across acute timepoints and follow-up; mood outcomes were collected repeatedly up to day 98. Results published (PubMed PMID:24699062).
Repeated intravenous ketamine infusions with dose-escalation stages (0.5 mg/kg infusions).
0.5 mg/kg IV over 40 minutes; stage 1 once weekly ×3; stage 2 twice weekly ×3.